The PROPHECI trial: a phase II, double-blind, placebo-controlled, randomized clinical trial for the treatment of pseudoxanthoma elasticum with oral pyrophosphate

被引:0
|
作者
Clotaire, Laetitia [1 ,2 ]
Rubera, Isabelle [1 ]
Duranton, Christophe [1 ]
Gal, Jocelyn [3 ]
Chamorey, Emmanuel [3 ]
Humeau, Helene [4 ]
Yamani, Samir [5 ]
Chiaverini, Christine [6 ]
Willoteaux, Serge [7 ]
Padovani, Bernard [8 ]
Mourozeau, Laurie [4 ]
Mainguy, Adam [4 ]
Baillif, Stephanie [9 ]
Martin, Ludovic [10 ,11 ]
Leftheriotis, Georges [1 ,12 ]
机构
[1] Univ Cote Azur, CNRS, LP2M, Nice, France
[2] Labs ProNutri, Res & Dev Dept, Carros, France
[3] Ctr Antoine Lacassagne, Stat Dept, Nice, France
[4] Ctr Hosp Univ Angers, Ophthalmol Dept, Angers, France
[5] Cote Azur Univ, Ctr Hosp Univ Nice, Dept Dermatol, Nice, France
[6] Univ Cote Azur, Ctr Hosp Univ Nice, Dermatol Dept, Nice, France
[7] Ctr Hosp Univ Angers, Radiol Dept, Angers, France
[8] Univ Cote Azur, Ctr Hosp Univ Nice, Radiol Dept, Nice, France
[9] Univ Cote Azur, Ctr Hosp Univ Nice, Ophthalmol Dept, Nice, France
[10] Ctr Hosp Univ Angers, PXE Natl Reference Ctr, Angers, France
[11] Ctr Hosp Univ Angers, Dermatol Dept, Angers, France
[12] Univ Cote Azur, Natl Ctr Rare Arterial Dis, Ctr Hosp Univ Nice, Nice, France
关键词
Double-blind randomized clinical trial; Pyrophosphate supplementation; Arterial calcification; Pseudoxanthoma elasticum; ECTOPIC MINERALIZATION; TISSUE; CALCIFICATION; PLASMA;
D O I
10.1186/s13063-024-08666-w
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background/aims.Pseudoxanthoma Elasticum (PXE, OMIM 264800) is an autosomal, recessive, metabolic disorder characterized by progressive ectopic calcification in the skin, the vasculature and Bruch's membrane. Variants in the ABCC6 gene are associated with low plasma pyrophosphate (PPi) concentration. There is currently no reference treatment for this chronic debilitating disease.Background/aims.Pseudoxanthoma Elasticum (PXE, OMIM 264800) is an autosomal, recessive, metabolic disorder characterized by progressive ectopic calcification in the skin, the vasculature and Bruch's membrane. Variants in the ABCC6 gene are associated with low plasma pyrophosphate (PPi) concentration. There is currently no reference treatment for this chronic debilitating disease.MethodsPROPHECI (PyROphosPHate supplementation to fight ECtopIc calcification in PseudoXanthoma Elasticum) is the first phase II, randomized, double-blind, placebo-controlled clinical trial (NTC 04868578) to evaluate the efficacy and safety of a daily oral PPi salt supplementation to attenuate and/or stabilize the progression of ectopic calcification in PXE patients. The primary endpoint is the change in arterial calcification volume quantified by non-contrast CT scan between baseline and 12 months of treatment. Secondary endpoints include the safety and efficacy of daily oral PPi administration on ocular and skin lesions and the evaluation of patients' quality of life.DiscussionThe PROPHECI trial aims to provide safety and efficacy data on the use of daily oral PPi to reduce or stabilize ectopic calcification in PXE. It also aims to validate the best markers to include in the design of future trials for the treatment of PXE and other parent diseases.Trial registrationTrial registration number: NCT 04868578.References can be found on the ClinicalTrials.gov website: https://clinicaltrials.gov/study/NCT04868578?cond=Pseudoxanthoma%20Elasticum&intr=pyrophosphate&rank=2Trial registrationTrial registration number: NCT 04868578.References can be found on the ClinicalTrials.gov website: https://clinicaltrials.gov/study/NCT04868578?cond=Pseudoxanthoma%20Elasticum&intr=pyrophosphate&rank=2
引用
收藏
页数:12
相关论文
共 50 条
  • [31] The Bexagliflozin Efficacy and Safety Trial (BEST): A Randomized, Double-Blind, Placebo-Controlled, Phase IIII, Clinical Trial
    McMurray, John J. V.
    Freeman, Mason W.
    Massaro, Joe
    Solomon, Scott
    Lock, Paul
    Riddle, Matthew C.
    Halvorsen, Yuan-Di C.
    DIABETES, 2020, 69
  • [32] A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression
    Calabrese, JR
    Keck, PE
    Macfadden, W
    Minkwitz, M
    Ketter, TA
    Weisler, RH
    Cutler, AJ
    McCoy, R
    Wilson, E
    Mullen, J
    AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (07): : 1351 - 1360
  • [33] Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial
    Pariser, David M.
    Bagel, Jerry
    Lebwohl, Mark
    Yosipovitch, Gil
    Chien, Elaine
    Spellman, Mary C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (06) : 1314 - 1320
  • [34] JinqiJiangtang tablets for prediabetes: A randomized, double-blind and placebo-controlled clinical trial
    Wang, Hui
    Guo, Liping
    Shang, Hongcai
    Ren, Ming
    Wang, Xuemei
    Wang, Dehui
    Chen, Jianzong
    Li, Shuanglei
    Chen, Liming
    Wang, Yue
    Liu, Zhi
    Zhai, Jingbo
    Song, Yuzhen
    Cao, Hongbo
    Zhang, Junhua
    Liu, Chunxiang
    Sun, Xiao
    Huo, Da
    Mu, Wei
    Zhang, Li
    Zheng, Wenke
    Yan, Xiaoyan
    Yao, Chen
    SCIENTIFIC REPORTS, 2017, 7
  • [35] CHOLECALCIFEROL SUPPLEMENTATION AND INFLAMMATION: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL
    Seibert, Eric
    Ulrich, Christof
    Trojanowicz, Bogusz
    Lehmann, Ulrike
    Dierkes, Jutta
    Stangl, Gabriele I.
    Girndt, Matthias
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [36] A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine
    Voss, Tiffini
    Lipton, Richard B.
    Dodick, David W.
    Dupre, Nicole
    Ge, Joy Yang
    Bachman, Robert
    Assaid, Christopher
    Aurora, Sheena K.
    Michelson, David
    CEPHALALGIA, 2016, 36 (09) : 887 - 898
  • [37] Immunomodulatory Effects of Saffron: A Randomized Double-Blind Placebo-Controlled Clinical Trial
    Kianbakht, S.
    Ghazavi, A.
    PHYTOTHERAPY RESEARCH, 2011, 25 (12) : 1801 - 1805
  • [38] Zinc supplementation in prediabetes: A randomized double-blind placebo-controlled clinical trial
    Ranasinghe, Priyanga
    Wathurapatha, Wasundara S.
    Galappatthy, Priyadarshani
    Katulanda, Prasad
    Jayawardena, Ranil
    Constantine, Godwin R.
    JOURNAL OF DIABETES, 2018, 10 (05) : 386 - 397
  • [39] A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of Omalizumab For Chronic Rhinosinusitis
    Mehta, N. J.
    Pinto, J.
    de Tineo, M.
    Baroody, F. M.
    Naclerio, R. M.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S201 - S201
  • [40] A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with Fibromyalgia
    Mease, Philip J.
    Russell, I. Jon
    Arnold, Lesley M.
    Florian, Hana
    Young, James P.
    Martin, Susan A.
    Sharma, Uma
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (03) : 502 - 514